GSK shares ease after plaintiff in first Zantac lawsuit drops case

GSK (GlaxoSmithKline) logo is seen in this illustration, August 10, 2022. REUTERS/Dado Ruvic/Illustration

LONDON, Aug 17 (Reuters) - Shares in GlaxoSmithKline fell slightly in early trading on Wednesday but stayed above recent lows after the plaintiff in the first lawsuit over the heartburn drug Zantac scheduled to go to trial agreed to drop his case. read more

Shares in the London-listed drugmaker were down 0.6% shortly after 0700 GMT. One trader said the news looked positive at first sight, although it could be a one-off.

Shares of GSK (GSK.L), Sanofi (SASY.PA), Pfizer (PFE.N) and Haleon (HLN.L) have taken a hit in recent weeks on investor concerns about thousands of lawsuits claiming the drug, which U.S. regulators pulled from the market in 2020, causes cancer.

Register now for FREE unlimited access to
Reporting by Lucy Raitano; editing by Danilo Masoni

Our Standards: The Thomson Reuters Trust Principles.